Role for c-Abl and p73 in the radiation response of male germ cellsHAMER, Geert; GADEMAN, Iris S; KAL, Henk B et al.Oncogene (Basingstoke). 2001, Vol 20, Num 32, pp 4298-4304, issn 0950-9232Article

Tyrosine kinase activity and transformation potency of bcr-abl oncogene productsLUGO, T. G; PENDERGAST, A.-M; MULLER, A. J et al.Science (Washington, D.C.). 1990, Vol 247, Num 4946, pp 1079-1082, issn 0036-8075, 4 p.Article

Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformationHEANEY, C; KOLIBABA, K; BHAT, A et al.Blood. 1997, Vol 89, Num 1, pp 297-306, issn 0006-4971Article

Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cellsGROSS, Alec W; RUIBAO REN.Oncogene (Basingstoke). 2000, Vol 19, Num 54, pp 6286-6296, issn 0950-9232Article

Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr/abl-positive leukaemia cellsRIORDAN, F. A; BRAVERY, C. A; MENGUBAS, K et al.Oncogene (Basingstoke). 1998, Vol 16, Num 12, pp 1533-1542, issn 0950-9232Article

Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoproteinMCWHIRTER, J. R; WANG, J. Y. J.Oncogene (Basingstoke). 1997, Vol 15, Num 14, pp 1625-1634, issn 0950-9232Article

The presence of the Rb c-box peptide in the cytoplasm inhibits p210^bcr-abl transforming functionGUO, X.-Y. D; BALAGUE, C; TAO WANG et al.Oncogene (Basingstoke). 1999, Vol 18, Num 8, pp 1589-1595, issn 0950-9232Article

ETUDE DES EFFETS ANTI/APOPTOTIQUES DES ONCOGENES BCR/ABL PAR UTILISATION DES MODELES DE TRANSFORMATION HEMATOPOIETIQUES IN VITRO IMPLICATION POTENTIELLE DES MOLECULES STAT = STUDY OF THE ANTI APOPTOTIC EFFECTS OF BCR/ABL ONCOGENES BY THE USE OF HEMATOPOIETIC MODELS OF TRANSFORMATION IN VITRO POTENTIEL IMPLICATION OF STAT FACTORSAhmed Fadlallah, Mina; Turhan, Ali.1999, 214 p.Thesis

Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes)YAPING WU; LIJUAN YU; MCMAHON, R et al.Human gene therapy. 1999, Vol 10, Num 17, pp 2847-2857, issn 1043-0342Article

The SH2-containing adapter protein GRB10 interacts with BCR-ABLREN YUAN BAI; JAHN, T; SCHREM, S et al.Oncogene (Basingstoke). 1998, Vol 17, Num 8, pp 941-948, issn 0950-9232Article

Regulation of p73 by c-Abl through the p38 MAP kinase pathwaySANCHEZ-PRIETO, Ricardo; SANCHEZ-AREVALO, Victor Javier; SERVITJA, Joan-Marc et al.Oncogene (Basingstoke). 2002, Vol 21, Num 6, pp 974-979, issn 0950-9232Article

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen : high efficacy of drug combinationsBRADEEN, Heather A; EIDE, Christopher A; O'HARE, Thomas et al.Blood. 2006, Vol 108, Num 7, pp 2332-2338, issn 0006-4971, 7 p.Article

Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human t-cell responsesPINILLA-LBARZ, Javier; KORONTSVIT, Tatyana; ZAKHALEVA, Victoriya et al.Haematologica (Roma). 2005, Vol 90, Num 10, pp 1324-1332, issn 0390-6078, 9 p.Article

The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cellsAICHBERGER, Karl J; MAYERHOFER, Matthias; PICKL, Winfried F et al.Blood. 2006, Vol 108, Num 10, pp 3538-3547, issn 0006-4971, 10 p.Article

Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patientsJIE QIANG GUO; LIAN, J; GLASSMAN, A et al.American journal of clinical pathology. 1996, Vol 106, Num 4, pp 441-448, issn 0002-9173, 7 p.Article

A common dhosphotyrosine signature for the Bcr-Ab1 kinaseGOSS, Valerie L; LEE, Kimberly A; MORITZ, Albrecht et al.Blood. 2006, Vol 107, Num 12, pp 4888-4897, issn 0006-4971, 10 p.Article

BCR-ABl and BCR proteins : biochemicl characterization and localizationDHUT, S; CHAPLIN, T; YOUNG, B. D et al.Leukemia. 1990, Vol 4, Num 11, pp 745-750, issn 0887-6924, 6 p.Article

Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristicsBAIJUN FANG; CHUNMEI ZHENG; LIANMING LIAO et al.Blood. 2005, Vol 105, Num 7, pp 2733-2740, issn 0006-4971, 8 p.Article

The development of imatinib as a therapeutic agent for chronic myeloid leukemiaDEININGER, Michael; BUCHDUNGER, Elisabeth; DRUKER, Brian J et al.Blood. 2005, Vol 105, Num 7, pp 2640-2653, issn 0006-4971, 14 p.Article

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translationNOTARI, Mario; NEVIANI, Paolo; PERROTTI, Danilo et al.Blood. 2006, Vol 107, Num 6, pp 2507-2516, issn 0006-4971, 10 p.Article

JAK-STAT signaling activated by Abl oncogenesDANIAL, N. N; ROTHMAN, P.Oncogene (Basingstoke). 2000, Vol 19, Num 21, pp 2523-2531, issn 0950-9232Article

Activation de la protéine p65NF-KappaB (Rel A) dans les cellules transformées par la protéine hybride p210BCR-ABL. Etude dans la lignée myéloïde DA1 = Activation of p65NF-KappaB protein in p210BCR-ABL transformed cells. Study in a myeloid cell lineHamdane, Malika; D'Halluin, J.-C.1996, 176 p.Thesis

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLWHITE, Deborah; SAUNDERS, Verity; LYONS, A. Bruce et al.Blood. 2005, Vol 106, Num 7, pp 2520-2526, issn 0006-4971, 7 p.Article

The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathwaysVOSS, J; POSERN, G; HANNEMANN, J. R et al.Oncogene (Basingstoke). 2000, Vol 19, Num 13, pp 1684-1690, issn 0950-9232Article

Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in micePETERS, David G; KLUCHER, Kevin M; PERLINGEIRO, Rita C. R et al.Oncogene (Basingstoke). 2001, Vol 20, Num 21, pp 2636-2646, issn 0950-9232Article